Ben Lamm

And it also does this poly, in addition to screening for specific variants, it also, in specific gene mutations,

It creates this like interesting kind of like polygenic kind of risk assessment that also says, hey, we know that some of these genes could lead to late stage Alzheimer's or could lead to these different other disease states.

Right.

You know, it's well, it's not an exact science because there's still environmental factors.

You do know that there are some people that have a predisposition to diabetes, certain cancers, Alzheimer's and whatnot.

And so we use this company called Orchid Health.

And it was awesome.

I was in so happy with the results and having a healthy kid.

I love it.

I called them up.

I was like, can I invest in you guys?

Yeah, I agree.

I agree.

It's hard.

It's complex.

And the technology is moving faster than regulation.

That doesn't mean we shouldn't do it, right?

It just means that we need to be thoughtful about it.

And so Colossal never wanted to be in that discussion.

So we said, OK, maybe our genome engineering tools could be applied to that.